Drugs / 3,4-methylenedioxymethamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01447472 | May 2003 → May 2009 | — | Parc de Salut Mar | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxymethamphetamine | “The synthetic psychostimulant MDMA (± 3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based...” PMID 23112822 ↗ Oct 2012 |
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01447472 ↗ |
| Action | Inhibit | “mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6)” PMID 23112822 ↗ Oct 2012 |
| Route | Oral | “A single oral weight-adjusted dose of MDMA was administered” PMID 23112822 ↗ Oct 2012 |
| Target | CYP2D6 | “mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6)” PMID 23112822 ↗ Oct 2012 |